There are 2949 resources available
739P - Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immuno-oncology: A real-world study on behalf of Meet-URO group (MeetUro-7b)
Presenter: Marco Stellato
Session: E-Poster Display
Resources:
Abstract
740P - Response assessment in advanced renal cell carcinoma (mRCC) patients (pts) treated by Nivolumab (N) + Ipilimumab (I): CT volumetric measurement versus RECIST 1.1 response criteria
Presenter: Quentin Minault
Session: E-Poster Display
Resources:
Abstract
741P - Clinical outcomes stratified by Charlson Comorbidity Index (CCI) score from a retrospective study of patients with advanced renal cell carcinoma (aRCC) who received cabozantinib as part of the UK Managed Access Program (MAP)
Presenter: Kate Fife
Session: E-Poster Display
Resources:
Abstract
742P - Activation of the WNT signaling pathway correlates with innate resistance to immune checkpoint therapies in clear cell renal cell carcinoma
Presenter: Xinan Sheng
Session: E-Poster Display
Resources:
Abstract
743P - Activity of systemic therapies after cabozantinib (CABO) in patients (pts) with metastatic renal cell carcinoma (mRCC)
Presenter: Luigi Cerbone
Session: E-Poster Display
Resources:
Abstract
744P - Association between gene expression signatures (sigs) and pembrolizumab (pembro) efficacy in patients (pts) with advanced urothelial cancer (UC)
Presenter: Petros Grivas
Session: E-Poster Display
Resources:
Abstract
745P - Patient-reported outcomes (PROs) from JAVELIN Bladder 100: Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC)
Presenter: Thomas Powles
Session: E-Poster Display
Resources:
Abstract
746P - EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors
Presenter: Peter O'Donnell
Session: E-Poster Display
Resources:
Abstract
747P - Association of TMB with efficacy of pembrolizumab (pembro) in patients (pts) with advanced urothelial cancer (UC): Results from KEYNOTE-045 and KEYNOTE-052
Presenter: Joaquim Bellmunt
Session: E-Poster Display
Resources:
Abstract
748P - Prognostic factors related to post-platinum atezolizumab for relapsed metastatic urothelial cancer (mUC) from the SAUL study
Presenter: Aristotelis Bamias
Session: E-Poster Display
Resources:
Abstract